<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04654234</url>
  </required_header>
  <id_info>
    <org_study_id>GASTO-1067</org_study_id>
    <nct_id>NCT04654234</nct_id>
  </id_info>
  <brief_title>Total-body PET/CT Imaging Using the uEXPLORER in Non-small Cell Lung Cancer Patients Treated by Neoadjuvant Chemotherapy Plus Nivolumab and Definitive Concurrent Chemoradiotherapy</brief_title>
  <official_title>Total-body PET/CT Imaging Using the uEXPLORER in Non-small Cell Lung Cancer Patients Treated by Neoadjuvant Chemotherapy Plus Nivolumab and Definitive Concurrent Chemoradiotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The prospective study aims to explore the value of total-body PET/CT dynamic imaging&#xD;
      (uExplorer) in assessing tumor metabolic heterogeneity and predicting prognosis for patients&#xD;
      with locally advanced, unresectable non-small cell lung cancer (stage III) treated by&#xD;
      neoadjuvant chemotherapy plus nivolumab and definitive concurrent chemoradiation therapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2020</start_date>
  <completion_date type="Anticipated">September 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>2 Years</target_duration>
  <primary_outcome>
    <measure>Tumor standard uptake value (SUV)</measure>
    <time_frame>From randomisation to 1 year after radiotherapy</time_frame>
    <description>The dynamic change of tumor SUV examined by total-body PET/CT (uExplorer)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Normal tissue standard uptake value (SUV)</measure>
    <time_frame>From randomisation to 1 year after radiotherapy</time_frame>
    <description>The dynamic change of tumor SUV examined by total-body PET/CT (uExplorer)</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Total-body PET/CT (uExplorer)</arm_group_label>
    <description>Patients with locally advanced NSCLC will receive total-body PET/CT (uExplorer) scans before, during and after the treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Total body PET/CT (uExplorer)</intervention_name>
    <description>A total-body positron emission tomography/computed tomography (PET/CT) scanner (uEXPLORER) with a 192-cm scan range was applied for cancer diagnosis, organ function assessment and treatment outcome prediction. The total-body PET scanner can acquire scans with lower administered activity or short acquisition time, total-body dynamic acquisition at a longer delayed time point, and high detectability of exiguous changes of the whole body, and tumor as well.</description>
    <arm_group_label>Total-body PET/CT (uExplorer)</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Locally advanced non-small cell lung cancer patients treated by neoadjuvant chemotherapy&#xD;
        plus nivolumab and definitive concurrent chemoradiation therapy&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Provision of signed, written and dated informed consent prior to any study specific&#xD;
             procedures;&#xD;
&#xD;
          -  Patients aged 18~75 years old;&#xD;
&#xD;
          -  had histologically or cytologically confirmed non-small cell lung cancer;&#xD;
&#xD;
          -  Without prior chemotherapy, radiotherapy, surgery, targeted therapy or immunotherapy;&#xD;
&#xD;
          -  Life expectancy ≥12 weeks;&#xD;
&#xD;
          -  World Health Organization (WHO) Performance Status of 0 or 1;&#xD;
&#xD;
          -  had unresectable stage III disease according to the 8th edition of the American Joint&#xD;
             Committee on Cancer staging system;&#xD;
&#xD;
          -  Women should be non-breast feeding during the study period;&#xD;
&#xD;
          -  Women of reproductive age (WOCBP) must agree to comply with the contraceptive method&#xD;
             during the study treatment and for a period of 5 months following the last&#xD;
             administration of the study treatment;&#xD;
&#xD;
          -  Men who have sex with WOCBP must agree to comply with the contraceptive method during&#xD;
             the study treatment and for 7 months after the last administration of the study&#xD;
             treatment;&#xD;
&#xD;
          -  Absolute neutrophil count ≥1500/uL, hemoglobin ≥9.0mg/dL, platelet ≥100000/uL;&#xD;
&#xD;
          -  Serum creatinine clearance &gt;50 mL/min by the Cockcroft-Gault formula (Cockcroft and&#xD;
             Gault 1976);&#xD;
&#xD;
          -  Serum bilirubin ≤1.5 x upper limit of normal (ULN), Aspartate Transaminase(AST) and&#xD;
             Alanine Transaminase(ALT) ≤2.5 x ULN;&#xD;
&#xD;
          -  Forced expiratory volume in 1 second (FEV1) ≥800ml;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Concurrent enrollment in another clinical study, unless it is an&#xD;
             observational(non-interventional) clinical study;&#xD;
&#xD;
          -  Mixed small cell and non-small cell lung cancer histology;&#xD;
&#xD;
          -  Prior exposure to any anti-programmed cell death protein(PD)-1 or anti- PD-L1&#xD;
             antibody;&#xD;
&#xD;
          -  Active or prior documented autoimmune disease within the past 2 years;&#xD;
&#xD;
          -  Active or prior documented inflammatory bowel disease (eg. Crohn's disease, ulcerative&#xD;
             colitis);&#xD;
&#xD;
          -  History of primary immunodeficiency;&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active&#xD;
             infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable&#xD;
             angina pectoris, cardiac arrhythmia, active peptic ulcer disease or gastritis, active&#xD;
             bleeding diatheses;&#xD;
&#xD;
          -  History of another primary malignancy within 5 years, except for adequately treated&#xD;
             basal or squamous cell carcinoma of the skin or cancer of the cervix in situ and the&#xD;
             disease under study;&#xD;
&#xD;
          -  Female patients who are pregnant, breast-feeding or male or female patients of&#xD;
             reproductive potential who are not employing an effective method of birth control;&#xD;
&#xD;
          -  Any situation not suitable for this study judged by researchers;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hui Liu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bo Qiu, MD</last_name>
    <phone>+86-020-87343031</phone>
    <email>qiubo@sysucc.org.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Daquan Wang, MD</last_name>
    <phone>+86-020-87343031</phone>
    <email>wangdq@sysucc.org.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hui Liu</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hui Liu, Prof.</last_name>
      <phone>+86-020-87343031</phone>
      <email>liuhui@sysucc.org.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90. doi: 10.3322/caac.20107. Epub 2011 Feb 4. Erratum in: CA Cancer J Clin. 2011 Mar-Apr;61(2):134.</citation>
    <PMID>21296855</PMID>
  </reference>
  <reference>
    <citation>Le Chevalier T, Arriagada R, Quoix E, Ruffie P, Martin M, Tarayre M, Lacombe-Terrier MJ, Douillard JY, Laplanche A. Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: first analysis of a randomized trial in 353 patients. J Natl Cancer Inst. 1991 Mar 20;83(6):417-23.</citation>
    <PMID>1847977</PMID>
  </reference>
  <reference>
    <citation>Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Yokoi T, Chiappori A, Lee KH, de Wit M, Cho BC, Bourhaba M, Quantin X, Tokito T, Mekhail T, Planchard D, Kim YC, Karapetis CS, Hiret S, Ostoros G, Kubota K, Gray JE, Paz-Ares L, de Castro Carpeño J, Wadsworth C, Melillo G, Jiang H, Huang Y, Dennis PA, Özgüroğlu M; PACIFIC Investigators. Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. N Engl J Med. 2017 Nov 16;377(20):1919-1929. doi: 10.1056/NEJMoa1709937. Epub 2017 Sep 8.</citation>
    <PMID>28885881</PMID>
  </reference>
  <reference>
    <citation>Forde PM, Chaft JE, Smith KN, Anagnostou V, Cottrell TR, Hellmann MD, Zahurak M, Yang SC, Jones DR, Broderick S, Battafarano RJ, Velez MJ, Rekhtman N, Olah Z, Naidoo J, Marrone KA, Verde F, Guo H, Zhang J, Caushi JX, Chan HY, Sidhom JW, Scharpf RB, White J, Gabrielson E, Wang H, Rosner GL, Rusch V, Wolchok JD, Merghoub T, Taube JM, Velculescu VE, Topalian SL, Brahmer JR, Pardoll DM. Neoadjuvant PD-1 Blockade in Resectable Lung Cancer. N Engl J Med. 2018 May 24;378(21):1976-1986. doi: 10.1056/NEJMoa1716078. Epub 2018 Apr 16. Erratum in: N Engl J Med. 2018 Nov 29;379(22):2185.</citation>
    <PMID>29658848</PMID>
  </reference>
  <reference>
    <citation>Liao ZX, Komaki RR, Thames HD Jr, Liu HH, Tucker SL, Mohan R, Martel MK, Wei X, Yang K, Kim ES, Blumenschein G, Hong WK, Cox JD. Influence of technologic advances on outcomes in patients with unresectable, locally advanced non-small-cell lung cancer receiving concomitant chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2010 Mar 1;76(3):775-81. doi: 10.1016/j.ijrobp.2009.02.032. Epub 2009 Jun 8.</citation>
    <PMID>19515503</PMID>
  </reference>
  <reference>
    <citation>Zhang X, Xie Z, Berg E, Judenhofer MS, Liu W, Xu T, Ding Y, Lv Y, Dong Y, Deng Z, Tang S, Shi H, Hu P, Chen S, Bao J, Li H, Zhou J, Wang G, Cherry SR, Badawi RD, Qi J. Total-Body Dynamic Reconstruction and Parametric Imaging on the uEXPLORER. J Nucl Med. 2020 Feb;61(2):285-291. doi: 10.2967/jnumed.119.230565. Epub 2019 Jul 13.</citation>
    <PMID>31302637</PMID>
  </reference>
  <reference>
    <citation>Zhang YQ, Hu PC, Wu RZ, Gu YS, Chen SG, Yu HJ, Wang XQ, Song J, Shi HC. The image quality, lesion detectability, and acquisition time of (18)F-FDG total-body PET/CT in oncological patients. Eur J Nucl Med Mol Imaging. 2020 Oct;47(11):2507-2515. doi: 10.1007/s00259-020-04823-w. Epub 2020 May 18.</citation>
    <PMID>32424483</PMID>
  </reference>
  <reference>
    <citation>Zhang X, Cherry SR, Xie Z, Shi H, Badawi RD, Qi J. Subsecond total-body imaging using ultrasensitive positron emission tomography. Proc Natl Acad Sci U S A. 2020 Feb 4;117(5):2265-2267. doi: 10.1073/pnas.1917379117. Epub 2020 Jan 21.</citation>
    <PMID>31964808</PMID>
  </reference>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>November 28, 2020</study_first_submitted>
  <study_first_submitted_qc>November 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 4, 2020</study_first_posted>
  <last_update_submitted>January 25, 2021</last_update_submitted>
  <last_update_submitted_qc>January 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Hui Liu</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <keyword>Non-small Cell Lung Cancer</keyword>
  <keyword>Total-body PET/CT</keyword>
  <keyword>uEXPLORER</keyword>
  <keyword>Nivolumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

